教育经历
· 2019.12 - 2019.12
Stanford University, USA - Postdoctoral
· 2019.12 - 2019.12
Nagoya University, JP - Ph. D.
工作经历
· 2019.12 - 2019.12
Tianjin Key Laboratory → Director
· 2019.12 - 2019.12
Tianjin University, Tianjin, CHINA → Professor
· 2019.12 - 2019.12
XenoPort, Inc. California, USA → Senior Research Scientist
· 2019.12 - 2019.12
Stanford University, California, USA → Postdoctoral fellow
· 2019.12 - 2019.12
Tokyo, JAPAN → Research Scientist
研究方向
· c) discovery and development of novel drug-delivery carriers and pharmaceutics based on supramolecular chemistry, d) computer aided molecular design and modeling for innovative drug discovery and mechanistic study of drug transporters.
· Specific areas include a) strategies for development of small molecular anti-cancer drugs for targeted therapy, b) design and development of actively transportable small molecule drugs or protein-drug conjugates,
· The research of the Gao group covers medicinal chemistry and molecular targeting, synthetic chemistry and organo catalysis, and computer-aided drug design, aimed at the discovery of functional drug delivery carriers and understanding mechanisms of molecular targeting.
学术成果
论文成果
-
[1]Computational studies of the binding modes of A(2A) adenosine receptor antagonists
-
[2][Advances in the study of A2B adenosine receptor antagonists].
-
[3]Mechanistic Study of Human Glucose Transport Mediated by GLUT1
-
[7]The discovery of a facile access to the synthesis of NSAID dendritic prodrugs
-
[11]3D-pharmacophore models for selective A(2A) and A(2B) adenosine receptor antagonists
-
[14]Pharmacophore Based Drug Design Approach as a Practical Process in Drug Discovery
-
[15]3D-QSAR study of corticotropin-releasing factor 1 antagonists and pharmacophore-based drug design
-
[16]3D Pharmacophore Based Virtual Screening of A(2A) Adenosine Receptor Antagonists
-
[18]A three-dimensional pharmacophore model for RXR alpha agonists
-
[19]Strategies on the Development of Small Molecule Anticancer Drugs for Targeted Therapy
-
[20]Molecular docking study of A(3) adenosine receptor antagonists and pharmacophore-based drug design